ABSTRACT
Objective:
Retroperitoneal fibrosis is a fibroinflammatory disease of an unknown origin and 2/3 of patients are idiopathic. In this study, the demographic, clinical and treatment features of patients diagnosed with idiopathic retroperitoneal fibrosis at Ankara University Faculty of Medicine Rheumatology Department were evaluated.
Methods:
Patients diagnosed with idiopathic retroperitoneal fibrosis between January 2000 and September 2019 were included in the study. Patient data were evaluated from hospital records retrospectively.
Results:
Seventeen patients were recruited in the study. The most common initial symptoms were pain and constitutional symptoms. All cases were diagnosed by imaging studies (computed tomography most commonly). Treatment with corticosteroid and concomitant azathioprine or cyclophosphamide at the time of diagnosis was initiated to all patients. In only 4 patients, treatment failure was recorded and rituximab and mycophenolate mofetil were used as a second line agent in these patients.
Conclusion:
The clinical and treatment features of our patients were compatible with the literature. The early diagnosis of retroperitoneal fibrosis is important to start treatment in order to prevent irreversible renal damage.
Keywords:
Idiopathic retroperitoneal fibrosis, computer tomography, magnetic resonance imaging
References
1Urban ML, Palmisano A, Nicastro M, Corradi D, Buzia C, Vaglio A. İdiopathic and secondary forms of retroperitoneal fibrosis: A diagnostic approach. Le Revue de medecine interne 2015;36:15-21.
2Van Bommel EF, Jansen I, Hendriksz TR, Aarnoudse AL. Idıopathic retroperitoneal fibrosis:prospective evaluation of incidence and clinicoradiologic presentation. Medicine 2009;88:193-201.
3Adnan S, Bouraoui A, Mehta S, Banerjee S, Jain S, Dasgupta B. Retroperitoneal fibrosis; a single-centre case experience with literature review. Rheumatology Advnaces in Practice 2018;0:1-8.
4Fernando A, Pattison J, Horsfield C, et al. A lot of questions (and a few answers) in retroperitoneal fibrosis. BJU Int 2016;117:16-9.
5Kermani T, Crownson C, Achenbcah S, Luthra H. Idiopathic retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment and outcomes. Mayo Clin roc 2011;86:297-303.
6Scheel PJ, Feeley N. Retroperitoneal fibrosis The clinical, laboratory and radiographic presentation. Medicine 2009;88:202-7.
7Vaglio A, Maritati F. Idiopathic retroperitoneal fibrosis. J Am Soc Nephrol 2016;27:1880-9.
8Vaglio A, Palmisano A,Corradi D, Salvarani C, Buzio C. Retroperitoneal fibrosis:evolving concepts. Rheum Dis Clin North Am 2007;33:803-17.
9van Bommel EF, Hendriksz TR, Huiskes AW, Zeegers AG. Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med 2006;144:101-6.
10Binder M, Uhl M, Wiech T, Kollert F, Thiel J, Sass JO, et al. Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis. Ann Rheum Dis 2012;71:311-2.
11Marcolongo R, Tavolini IM, Laveder F, Busa M, Noventa F, Bassi P, et al. Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases. Am J Med 2004;116:194-7.
12Vaglio A, Catanoso MG, Spaggiari L, Magnani L, Pipitone N, Macchioni P, et al. Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis. Arthritis Rheum 2013;65:2469-75.
13Maritati F, Corradi D, Versari A, Casali M, Urban ML, Buzio C, et al. Rituximab therapy for chronic periaortitis. Ann Rheum Dis 2012;71:1262-4.
14Wallace ZS, Naden RP, Chari S, Chai HK, DellaTorre E, Dicaire JF, et al. The 2019 American College of Rheumatology/European League against Rheumatism Classification Criteria for IgG4 related disease. Ann Rheum Dis 2020;7-19.
15Koo Bs, Koh YW, Kim YJ, Kim YG, Lee CK. Clinicopathologic characteristics of IgG4-related retroperitoneal fibrosis among patients initially diagnosed as having idiopathic retroperitoneal fibrosis. Modern Rheumatology 2015;25:194-8.
16Zen Y, Onodera M, Inoue D, Kitao A, Matsui O, Nohara T, et al. Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4. Am J Surg Pathol. 2009;33:1833-9.
